On the afternoon of 23 June, the 2020 inaugural Shenzhen High-Tech and High-Growth Forum, themed "Saluting 40 Years – Joining Hands to Win the Post-Pandemic Era", organized by the Shenzhen Shang General Chamber of Commerce, the Shenzhen Commercial Federation and the Top Ten Industrial Alliances of Shenzhen Shang, was successfully held at the International Conference Center of Kexing Science Park in Shenzhen. Dr. Hu Junyuan, Chairman of Beike Biotech, attended as Executive Chair of the Shenzhen Shang Life and Health Industry Alliance and delivered a keynote address titled "Breakthrough and Reconstruction".
As one of the core sub-forums of this summit, the "Heroes Against the Pandemic, Breakthroughs in High Tech" forum drew significant attention. Many heavyweights from the industry came together to discuss the highlights of science and technology in the fight against the pandemic, identify new opportunities for enterprises in crisis and create new outcomes amid change.
At the sub-forum, Dr. Hu Junyuan, Chairman of Beike Biotech, delivered an excellent keynote titled "Breakthrough and Reconstruction", in which he, together with the guests present, gave an in-depth interpretation of frontier areas including the life sciences and biopharmaceutical industry, around the three core themes of "people", "technology" and "life". He spoke about the breakthrough progress and outcomes that stem cells achieved in treating severe COVID-19 patients during the fight against the pandemic, and showcased Beike Biotech's work and results in the COVID-19 response.
Dr. Hu's outstanding keynote left guests in attendance with a strong sense of the appeal of biotechnology and full of hope for the future of biopharmaceuticals and cell therapy.
As a National High-Tech Enterprise specializing in the clinical translation of personalized cell therapy technologies, Beike Biotech has consistently aimed to become a leading enterprise driving the clinical translation of cell therapy technology. The Shenzhen Comprehensive Cell Bank, established and operated by Beike Biotech, is the infrastructure for Shenzhen's life and health industry approved by the Shenzhen Development and Reform Commission. Today, Beike Biotech has built up a "1 bank, 1 center, 1 platform" (Comprehensive Cell Bank + Regional Cell Preparation Center + Cell Quality Inspection Platform) business architecture, providing cell resource storage, preparation and testing services in many provinces and cities across China.
In the area of medical health, since 2009 Beike Biotech has carried out systematic research and new drug development on multiple intractable diseases, covering process validation, quality research, stability research, pharmacology research and toxicology research of mesenchymal stem cells. Among these, the research outcome "Key Technical Innovation and Clinical Application of Allogeneic Mesenchymal Stem Cells in Treating Refractory Lupus Erythematosus" received the 2019 National Technological Invention Award. After the COVID-19 outbreak this year, Beike Biotech responded immediately and was approved for the Guangdong Department of Science and Technology's "Emergency Special Project on Scientific and Technological Tackling for the Prevention and Control of Novel Coronavirus Infection", as well as the Kunming Science and Technology Bureau's "Special Project on Scientific and Technological Prevention and Control of Novel Coronavirus Pneumonia". In May this year, the new drug clinical registration application for the product "Human Umbilical Cord Mesenchymal Stem Cells for Injection for the Treatment of Refractory Systemic Lupus Erythematosus", independently developed by Beike Biotech, was officially accepted by the Center for Drug Evaluation of the National Medical Products Administration, becoming China's first stem cell product targeting refractory systemic lupus erythematosus.
The forum was held to salute the 40th anniversary of the Shenzhen Special Economic Zone, support the construction of the dual zones, boost entrepreneurs' confidence in development and, in the post-pandemic era, unite Shenzhen Shang in exploring new models and approaches for industrial innovation and upgrading. The forum drew nearly 200 participants, including the heads of many well-known Shenzhen Shang enterprises, experts, scholars and media reporters.
